By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Statin > Pitavastatin

Pitavastatin

GMJ
Last updated: 01/06/2026 20:19
By
GMJ News Desk
Share
5 Min Read
SHARE
3 min read|622 words

Pitavastatin: A Comprehensive Drug Profile

What is Pitavastatin?

Pitavastatin is a prescription medication belonging to a class of drugs called statins, also known as HMG-CoA reductase inhibitors. It is primarily used to lower cholesterol levels in the blood and reduce the risk of cardiovascular disease. Pitavastatin is considered one of the newer, more potent statins available for treating high cholesterol and related cardiovascular conditions.

Uses

Pitavastatin is approved for several cardiovascular-related conditions:

  • Primary hyperlipidemia: Treatment of elevated LDL cholesterol, total cholesterol, and triglycerides in patients with high cholesterol levels
  • Mixed dyslipidemia: Management of patients with multiple lipid abnormalities, including low HDL cholesterol combined with high LDL cholesterol
  • Primary prevention of cardiovascular disease: Reducing the risk of heart attack and stroke in patients with elevated cholesterol and additional cardiovascular risk factors
  • Secondary prevention: Prevention of cardiovascular events in patients with established coronary heart disease or other atherosclerotic conditions
  • Familial hypercholesterolemia: Treatment of inherited forms of high cholesterol as part of comprehensive lipid management

How it works

Pitavastatin works by blocking an enzyme called HMG-CoA reductase, which is responsible for producing cholesterol in the liver. By inhibiting this enzyme, the medication reduces the liver’s ability to manufacture cholesterol, leading to lower blood cholesterol levels. Additionally, this mechanism causes the liver to increase the number of LDL receptors, which helps remove more cholesterol from the bloodstream.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Muscle pain or weakness
  • Headache
  • Back pain
  • Constipation
  • Diarrhea
  • Joint pain
  • Nausea
  • Cold-like symptoms

Serious side effects to watch for:

  • Severe muscle pain, tenderness, or weakness (potential sign of rhabdomyolysis)
  • Dark-colored urine or decreased urination
  • Unusual fatigue or weakness
  • Yellowing of skin or eyes (jaundice)
  • Severe abdominal pain

Warnings and precautions

  • Pregnancy and breastfeeding: Pitavastatin is contraindicated during pregnancy and breastfeeding, as cholesterol is essential for fetal development and the drug may pass into breast milk
  • Liver disease: Patients with active liver disease or unexplained persistent elevations in liver enzymes should not use pitavastatin
  • Muscle disorders: Individuals with a history of muscle disorders or previous statin-related muscle problems should use pitavastatin with caution
  • Kidney impairment: Dosage adjustments may be necessary for patients with moderate to severe kidney dysfunction
  • Age considerations: Elderly patients may be more susceptible to muscle-related side effects and should be monitored closely

Interactions

Pitavastatin can interact with several medications and supplements:

  • Cyclosporine: Significantly increases pitavastatin levels, requiring dose reduction or alternative therapy
  • Gemfibrozil: May increase the risk of muscle toxicity when combined with pitavastatin
  • Warfarin: Pitavastatin may enhance the anticoagulant effect, requiring more frequent INR monitoring
  • Niacin (high doses): Combined use may increase the risk of muscle-related side effects
  • Rifampin: May decrease pitavastatin effectiveness by increasing its metabolism
  • Red yeast rice: Contains natural statins and may increase the risk of muscle toxicity
  • Grapefruit juice: Unlike some other statins, pitavastatin has minimal interaction with grapefruit juice
  • Erythromycin: May increase pitavastatin levels, though the interaction is generally less significant than with other statins

Check interactions with the GMJ Interaction Checker

Dosage

The typical starting dose of pitavastatin for adults is 2 mg once daily, taken with or without food. The dosage range is generally 1 mg to 4 mg once daily, depending on the patient’s cholesterol levels and treatment response. For patients with kidney impairment, the maximum recommended dose is 2 mg daily. Elderly patients may start with lower doses. The medication is usually taken in the evening, though it can be taken at any time of day. Dosage should always be individualized and determined by a healthcare provider based on the patient’s specific condition, other medications, and treatment goals.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Pitavastatin." GMJ News — Georgian Medical Journal, 1 June 2026. https://news.gmj.ge/drug/pitavastatin-4/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Endometriosis Affects 10% of Women Yet Faces Chronic Under-recognition, BBC Investigation Reveals

BBC investigation reveals endometriosis affects 10% of women yet faces chronic under-recognition,…

Medical School Diversity Gains Not Translating to Diverse Physician Workforce

Despite medical schools successfully diversifying enrollment, these gains aren't translating to physician…

Maternity Staff Used Offensive Terms for Patients, BBC Investigation Reveals

BBC Panorama investigation reveals maternity staff at Nottingham University Hospitals NHS Trust…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Pitavastatin

By
GMJ News Desk
01/06/2026

Fluvastatin

By
GMJ News Desk
01/06/2026

Pravastatin

By
GMJ News Desk
01/06/2026

Pravastatin

By
GMJ News Desk
01/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up